One hundred and nineteen elderly patients with hip fractures scheduled for a total hip arthroplasty were randomized to receive a fascia iliaca compartment blockade (FICB) and dexmedetomidine (DEX), FICB only, or control for the management of pain and inflammation. Outcomes of interest included inflammatory markers, pain at rest and during motion on a Visual Analog Scale (VAS), and sleep quality as measured with the Pittsburgh Sleep Quality Index. Results revealed all outcomes to be significantly in favour of the FICB+DEX group. No significant differences in adverse events were observed among the three groups.